Stifel Reiterates Buy on BioMarin (BMRN) Following Bridgebio BBIO) Results: 'the main question with infigratinib continues to be safety'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $118.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
